Editorial: the potential of irisin as a therapeutic for diabetes

This editorial, brought to MedChemNet members by Future Medicinal Chemistry, highlights some of the current research into potential therapeutics for type 2 diabetes mellitus, including irisin.


Diabetes and obesity-related diseases are a major drain on healthcare resources; it is reported that around 350 million people suffer from diabetes globally, being Type 2 diabetes mellitus (T2DM) the most prevalent. Given that current remedies for diabetes are suboptimal, it is of paramount importance to explore some novel therapeutic targets as well as to promote preventative measures, such as dietary- and exercise-related approaches. T2DM develops once there are increases in peripheral insulin resistance, which is accompanied with pancreatic islet demise. In this regard, dysregulation of hepatic metabolism and islet function contributes critically to insulin resistance and insulin insufficiency, respectively, the major risk factors for the progression to the pathogenesis of T2DM; therefore, preservation of the liver and islet functions is a key strategy for the management of T2DM.

Read the full editorial from Future Medicinal Chemistry here

Leung PS. The potential of irisin as a therapeutic for diabetes. Future Medicinal Chemistry 9(6) (2017) 

Go to the profile of Future Medicinal Chemistry

Future Medicinal Chemistry

Journal, Future Science Group

Future Medicinal Chemistry provides a monthly point of access to commentary and debate for this ever-expanding and diversifying community. The journal showcases milestones in pharmaceutical R&D and features expert analysis of emerging research – from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents.

No comments yet.